RxDoctor Payments Data

Jien Shim, MD

Endocrinology, Diabetes & Metabolism · Menlo Park, CANPI 1275875957

Payments from drug & device makers

$656in general payments, 2019–2025

Across 12 payments — averaging $54.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$247
  • Amgen$132
  • Insulet Corporation$95
  • Acella Pharmaceuticals, LLC$67
  • Medtronic$57
  • Abbott$38
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$656100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$656 in reported general payments places this provider in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$365,054
Medicare patients
867
Services billed
9,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide124$161,971
OzempicSemaglutide107$146,883
JardianceEmpagliflozin58$77,447
TrulicityDulaglutide45$70,667
RybelsusSemaglutide29$49,656
FarxigaDapagliflozin Propanediol27$43,528
TymlosAbaloparatide13$42,225
JanuviaSitagliptin Phosphate19$28,154
Tresiba Flextouch U-100Insulin Degludec44$24,148
Cinacalcet Hcl14$15,192
Tresiba Flextouch U-200Insulin Degludec13$10,607
LyumjevInsulin Lispro-Aabc13$9,624
Cequr SimplicityBolus Insulin Pump, 200 Unit15$8,146
Humalog Kwikpen U-100Insulin Lispro33$7,341
TradjentaLinagliptin11$6,868

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Menlo Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →